Patent Challenges – PharmaLive

Gilead Versus HHS: Gilead Loses 2nd Patent Invalidation Challenge

Business, Department of Health and Human Services (HHS), Lawsuits, Patent Challenges, Trump Administration, U.S. Centers for Disease Control and Prevention, U.S. Patent Trial and Appeal Board (PTAB)

Gilead Sciences lost yet another challenge to the company’s U.S. patent to Truvada for HIV prevention, or PrEP.

February 21, 2020/by BioSpace

Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

Blockbusters, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Clinical Trial Endpoints, Clinical Trials, CNS damage, MS with walking impairment, Multiple Sclerosis, Neurology, Patent Challenges, R&D, Secondary Endpoints, Shares, U.S. Patent Trial and Appeal Board (PTAB)

Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.

February 6, 2020/by BioSpace

Alexion fortifies rare blood disorder drugs business

Acquisitions, Analysts, Business, Deals, Hemolytic Uremic Syndrome, Patent Challenges, Rare Blood Disorders, Rare Diseases, Shares, U.S. Federal Trade Commission (FTC)

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

October 16, 2019/by Reuters Health

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

Blockbusters, Copycats, Legal, Patent Challenges, Rheumatoid Arthritis

A U.S. judge upheld two patents relating to Amgen Inc.’s blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

August 9, 2019/by Reuters Health

U.S. court rejects Alvogen’s patent challenge for Celgene’s cancer drug

Analysts, Blockbusters, Business, Financials, M&A, Multiple Myeloma, Patent Challenges, Shares

The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.

March 14, 2019/by Reuters Health

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech, Business, Cholesterol, Juries, Legal, Patent Challenges, Trials

Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.

February 25, 2019/by Reuters Health